Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From May 2019 to May 2024
TKT to Present at SG Cowen Securities' 25th Annual HealthCare
Conference
CAMBRIDGE, Mass., March 9 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) today announced that the company will present at SG Cowen
Securities' 25th Annual Healthcare Conference being held in Boston,
Massachusetts, March 14-17, 2005. Michael J. Astrue, President and Chief
Executive Officer will present an overview and update of TKT's business
activities and product pipeline at 11:20 a.m. - 12:00 p.m. Eastern Time on
Wednesday, March 16, 2005. A live audio webcast of this presentation will be
available at http://www.tktx.com/ on TKT's Investor Information website under
the Events category. A replay will be available for approximately 30 days
after the webcast.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused
on researching, developing and commercializing treatments for rare diseases
caused by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com/.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
Contact:
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/
DATASOURCE: Transkaryotic Therapies, Inc.
CONTACT: Daniella M. Lutz, Corporate Communications Manager of
Transkaryotic Therapies, Inc., +1-617-349-0205
Web site: http://www.tktx.com/
Company News On-Call: http://www.prnewswire.com/comp/120657.html